The most current report from Reports & Insights, "Gastric Cancer Treatment Market: Opportunity Analysis and Future Assessment 2023-2031," offers unique information on the market and includes in-depth information about potential challenges as well as future market chances and prospects. It also discusses current trends and the effects of numerous factors on the development of the Gastric Cancer Treatment market. Additionally, the research presents in-depth information about the top competitors vying for its readers' attention in the industry.
The global gastric cancer treatment market in 2020 is estimated for more than US$ 3.2 Bn and expected to reach a value of US$ 10.6 Bn by 2028 with a significant CAGR of 16.0%
Reports and Insights (R&I) has published a new report titled, “Global Gastric Cancer Treatment Market: Opportunity Analysis and Future Assessment 2023 to 2031”
Global Gastric Cancer Treatment Market, by Treatment Type (Chemotherapy, Targeted Drugs Therapy, Radiation Therapy), By distribution channels (Hospitals, Clinics, long-term care centers, others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
As per the report, the growing prevalence of gastric adenocarcinoma and the availability of new treatment options are the main factors driving the growth of the gastric cancer treatment market. According to the American Cancer Society, approximately 27,510 new cases of gastric cancer are expected to be diagnosed in the U.S. in 2019. As per the Globocan registry, globally 1,033,701 new cases of gastric cancer were diagnosed in 2018, and gastric cancer constitutes 5.7% of all new cancer cases. Gastric cancer is usually diagnosed at an advanced stage with distant metastasis.
Systemic chemotherapy is the first line of treatment in patients with metastatic gastric adenocarcinoma. 5-fluorouracil is the first chemotherapeutic agent of choice against metastatic gastric adenocarcinoma. Recent advances in treatment such as immune checkpoint inhibitors have achieved a significant increase in response rate to the treatment. However, the cure of metastatic gastric adenocarcinoma is difficult with chemotherapy alone.
This Gastric Cancer Treatment Market Research/Analysis Report Contains Answers to your following Questions
- Which Manufacturing Technology is used for Gastric Cancer Treatment? What Developments Are Going On in That Technology? Which Trends Are Causing These Developments?
- Who Are the Global Key Players in This Gastric Cancer Treatment Market? What are Their Company Profile, Their Product Information, and Contact Information?
- What Was Global Market Status of Gastric Cancer Treatment Market? What Was Capacity, Production Value, Cost and PROFIT of Gastric Cancer Treatment Market?
- What Is Current Market Status of Gastric Cancer Treatment Industry? What’s Market Competition in This Industry, Both Company, and Country Wise? What’s Market Analysis of Gastric Cancer Treatment Market by Taking Applications and Types in Consideration?
- What Are Projections of Global Gastric Cancer Treatment Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about Import and Export?
- What Is Gastric Cancer Treatment Market Chain Analysis by Upstream Raw Materials and Downstream Industry?
- What Is Economic Impact On Gastric Cancer Treatment Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends?
- What Are Market Dynamics of Gastric Cancer Treatment Market? What Are Challenges and Opportunities?
- What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Gastric Cancer Treatment Industry?
Current treatment strategies are thus aimed at relieving symptoms and prolong survival. Improving survival rates is another major factor pushing the gastric cancer treatment market. As per the results of the latest clinical trials the median survival rate for metastatic gastric cancer is 6 to 13 months. The expanding aging population is another key factor driving the growth of the gastric cancer treatment market growth. As per American Cancer Society findings of 6 of every 10 people diagnosed with stomach cancer, each year are 65 or older.
Furthermore, Reports and Insights (R&I) Study identifies that, in spite of the availability of advanced treatment options, gastric adenocarcinoma remains the second highest cause of cancer deaths in the world. Until the late 1930s, stomach cancer was the leading cause of cancer death in the United States.
However, the incidence rate for gastric cancer is falling and the rate varies in different geographic regions. Incidence rates are found to be higher in developing countries, and the caseload in developing countries is increasing. Helicobacter pylori (H. pylori) infection is a major risk factor for gastric cancer.
Although chemotherapy is recommended primarily for metastatic gastric adenocarcinoma treatment, the penetration of new therapies such as targeted therapy with monoclonal antibodies and kinase inhibitors is increasing. FDA Approval of new Immune checkpoint inhibitor therapy in 2018 would further provide traction to the market.
The treatment strategy for metastatic gastric adenocarcinoma is considered individually based on the physical and socioeconomic status of patients and on the symptoms. Besides many drugs are being designed to target the molecular pathways involved in the progression of metastatic gastric cancer, which is expected to be launched in the market during the forecast period.
R&I Study identifies some of the key participating players in the gastric cancer treatment market globally are Merck, Pfizer, F. Hoffman-La Roche AG, Eli Lilly and Company, Novartis AG, Mylan Pharmaceuticals, Pfizer Inc., Actavis Pharma, Inc., AbbVie, etc., among others.
To Understand How Covid-19 Impact Is Covered in This Report, Ask for Customization: https://reportsandinsights.com/free-customization/1228
Regional Analysis Covered in this report:
The geographical analysis of the Global Gastric Cancer Treatment market provided in the report is just the right tool that competitors can use to discover untapped sales and business expansion opportunities in different regions and countries. Each regional and country-wise Gastric Cancer Treatment market considered for research and analysis has been thoroughly studied based on market share, future growth potential, CAGR, market size, and other important parameters. Every regional market has a different trend or not all regional markets are impacted by the same trend. Taking this into consideration, the analysts authoring the report have provided an exhaustive analysis of specific trends of each regional Gastric Cancer Treatment market.
About Reports and Insights (R&I):
Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Contact Us:
Reports and Insights (R&I)
Tel: +1-(281)-619-8646
For Sales Queries: [email protected]
For New Topics and Other Info: [email protected]
Global Metastatic Gastric Cancer Treatment Market: OverviewGastric cancer (GC) is the second-leading cause of cancer-related mortality worldwide and is also responsible for a significantly high cancer burden, as measured by disability-adjusted life years lost.
The World Health Organization estimates that in 2018, gastric cancer accounted for 783,000 deaths worldwide.
Approximately 50 to 65% of GC patients present with locally advanced or metastatic disease, and the majority would have systemic disease at some time during the course of their illness.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=80552Gastric cancer incidence and mortality are highly variable by region and highly dependent on diet and Helicobacter pylori infection.
In developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females.Key Drivers and Restrains of Global Metastatic Gastric Cancer Treatment MarketFavorable reimbursement in developed countries, adoption of combination therapy such as chemotherapy with immunotherapy drugs that effectively work in the stage III or IV gastric cancer.
Doctors are also opting for chemotherapy before surgery, called neoadjuvant therapy, or after surgery, called adjuvant therapy to treat metastatic gastric cancer, which is likely to drive the metastatic gastric cancer treatment market.However, low survival rate of metastatic gastric cancer and high cost associated with the immunotherapy treatment procedures are likely to restraint the market during the forecast periodRequest COVID Analysis on Metastatic Gastric Cancer Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=80552North America to Account for Major Share of Global Metastatic Gastric Cancer Treatment MarketIn terms of region, the global metastatic gastric cancer market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & AfricaNorth America is projected to dominate the global market during the forecast period.
The region is anticipated to account for a significant share of the global market due to wide availability of immunotherapy drugs and favorable reimbursement scenario.The market in Asia Pacific is driven by sustainable growth trends across all clinical fields in countries in the region and consequent increase in number of cases.
What are the symptoms of Stomach/Gastric Cancer?
Why is stomach/Gastric Cancer difficult to identify?
What are the causes of Stomach/Gastric Cancer?
Which factors increase the risk of Stomach/Gastric Cancer Stomach/Gastric Cancer Treatment in Gurugram
